Results 91 to 100 of about 1,337,614 (304)
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan+9 more
wiley +1 more source
Lung Cancer Death Rates among Non-Smokers and Pipe and Cigarette Smokers [PDF]
Percy Stocks, J. M. Campbell
openalex +1 more source
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts+8 more
wiley +1 more source
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira+14 more
wiley +1 more source
Lung Cancer Mortality and the Length of Cigarette Ends [PDF]
Richard E. Doll+3 more
openalex +1 more source
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga+8 more
wiley +1 more source
Mortality from Lung Cancer in the Netherlands during and after the Last War
R Korteweg
openalex +1 more source
A Practical Diagnostic Method in Lung-Cancer Detection [PDF]
S M Farber, Orville F. Grimes
openalex +1 more source
We investigated whether hypomethylating agents (HMAs) used in myeloid malignancies induce somatic retrotransposition. Our findings indicate that HMA treatment increases L1‐encoded protein expression but does not lead to detectable de novo retrotransposition events in either patient samples or cell lines.
Šárka Pavlová+14 more
wiley +1 more source
Expert Consensus on the Diagnosis and Treatment of Bone Metastasis in Lung Cancer (2019 Version)
The Youth Specialists Committee of Lung Cancer, Beijing Medical Award Foundaton, Chinese Lung Cancer Union
doaj +1 more source